Clinical Trial Update: Revlimid in Transfusion Dependent Patients [Phase 2]

View source ↗

Summary

Phase 2 results for lenalidomide (Revlimid) in transfusion-dependent myelodysplastic syndrome patients have been completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Columbia University | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-07-20